Amicus Therapeutics
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Amicus Therapeutics is Lower Risk. The company does not yield to political activism in shaping corporate governance, preventing initiatives that potentially alienate consumers, divide employees, and harm shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Overall, Amicus Therapeutics does not embrace corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach protects free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportHas canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.
Amicus Therapeutics has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (1).
Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.
Amicus Therapeutics does not appear to discriminate against charitable organizations based on views or beliefs. The company’s charitable giving focus ares are healthcare-related humanitarian organizations; healthcare industry associations; academic centers engaged in disease and patient education; patient, professional, medical, and scientific associations; and community service organizations (1).
Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.
Amicus Therapeutics appears to prioritize diversity over merit in its business structure through the establishment of gender and racial targets for its leadership composition. From its ESG Report: Its DEI initiatives include “ensur[ing] diverse hiring slates for all roles, increasing the number of diverse hires, especially for Director and above positions” (1). The company appears to prioritize diversity over merit in its business structure through the establishment of racial targets for its leadership composition. The company is seeking “Board of Directors (60% diverse) and in executive leadership (46% diverse)” (2). The company does not provide viewpoint protections for its employees (3).
Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.
Amicus Therapeutics supports DEI within its business practices. From its ESG Report: “Our ‘Three Pillars of DEI’ are interwoven into our Amicus culture and expand one person, one word, and one act at a time” (1). The company supports ESG within its business practices. From its ESG Report: “Building strong ESG practices and oversight into our scientific and business activities creates a culture of integrity at every level of the organization, while safely and effectively delivering on our founding beliefs” (2).
Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.
Amicus Therapeutics has not used corporate funds to advance ideological causes, organizations, or policies (1).
Board Bias
Expand Summary
1792 Exchange has not yet compiled data about the board of directors or political contributions of leadership for this company.